Medtronic (NYSE: MDT) is one of 46 public companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Medtronic to related businesses based on the strength of its analyst recommendations, profitability, valuation, earnings, dividends, risk and institutional ownership.
Risk and Volatility
Medtronic has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Medtronic’s rivals have a beta of 1.58, indicating that their average stock price is 58% more volatile than the S&P 500.
This table compares Medtronic and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
81.2% of Medtronic shares are held by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 0.3% of Medtronic shares are held by insiders. Comparatively, 20.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Medtronic pays an annual dividend of $1.84 per share and has a dividend yield of 2.3%. Medtronic pays out 40.0% of its earnings in the form of a dividend. As a group, “Electromedical equipment” companies pay a dividend yield of 1.9% and pay out 40.7% of their earnings in the form of a dividend. Medtronic has increased its dividend for 40 consecutive years. Medtronic is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Valuation & Earnings
This table compares Medtronic and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Medtronic||$29.71 billion||$4.03 billion||17.30|
|Medtronic Competitors||$1.10 billion||$121.87 million||-38.42|
Medtronic has higher revenue and earnings than its rivals. Medtronic is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent ratings and target prices for Medtronic and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Medtronic currently has a consensus target price of $91.24, suggesting a potential upside of 14.66%. As a group, “Electromedical equipment” companies have a potential upside of 19.85%. Given Medtronic’s rivals higher probable upside, analysts clearly believe Medtronic has less favorable growth aspects than its rivals.
Medtronic beats its rivals on 10 of the 15 factors compared.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.